霍惠子

[關键词] 溃疡性结肠炎;美沙拉嗪;益生菌;炎症因子;肠道菌群;免疫功能

[中图分类号] R574.2          [文献标识码] B          [文章编号] 1673-9701（2021）14-0111-04

Effect analysis of probiotics combined with mesalazine on patients with ulcerative colitis and its effect on NGAL and MUC2 protein

HUO Huizi

Department of Pharmacy，the Central Hospital of Jiamusi City in Heilongjiang Province， Jiamusi   154002， China

[Abstract] Objective To explore the clinical efficacy of probiotics combined with mesalazine on patients with ulcerative colitis and the effects on neutrophil gelatinase-related lipid carrier protein （NGAL） and intestinal mucin 2 （MUC2） levels. Methods A total of 98 patients with ulcerative colitis admitted to our hospital from June 2018 to June 2020 were collected as research objects. They were randomLy divided into the observation group and the control group， with 49 cases in each group. The control group was treated with mesalazine， while the observation group was treated with probiotics combined with mesalazine. The clinical efficacy， NGAL， MUC2， flora distribution， T lymphocyte subsets and the incidence of adverse reactions of the two groups of patients were recorded and compared. Results The total effective rate was 89.80% （44/49） in the observation group， which was higher than 71.43% （35/49） in the control group（P<0.05）. After treatment， NGAL was lower in the observation group than that in the control group， and MUC2 was higher than that in the control group（P<0.05）. After treatment，Bifidobacterium and Lactobacillus were higher in the observation group than those in the control group， while Enterococcus faecalis and Escherichia coli were lower than those in the control group（P<0.05）. After treatment， the T lymphocyte subsets CD3+， CD4+， CD4+/CD8+ were higher in the observation group than those in the control group，while CD8+ was lower than that in the control group（P<0.05）. During the treatment， the incidences of adverse reactions in the observation group and the control group were 16.34% （8/49） and 10.20% （5/49）， respectively（P>0.05）. Conclusion Probiotics combined with mesalazine is significantly effective in treating patients with ulcerative colitis. It can reduce the inflammatory level of the body， adjust the imbalance of intestinal flora of patients， and improve the immune function level of patients. The treatment is safe and can be popularized clinically.

[Key words] Ulcerative colitis; Mesalazine; Probiotics; Inflammatory factors; Intestinal flora; Immune function

溃疡性结肠炎是一种下消化道的炎性疾病，是出现在结肠和直肠的肠黏膜及黏膜下层的实质性病变[1-2]。患者发病后会出现典型的下消化道症状，进一步通过肠镜检查显现出结肠、直肠部位的溃疡性病灶[3-4]。根据流行病学的调查研究显示，近些年随着各种基础疾病的影响以及患者不良生活习惯的形成，溃疡性结肠炎的发病人群逐年增多，且各年龄阶层的患者人群均有发病，并且该病的治疗有一定的难度，已引起了临床的高度关注[5]。溃疡性结肠炎的常规治疗主要有糖皮质激素抗炎、免疫增强调节等治疗手段[4]，其中美沙拉嗪是溃疡性结肠炎的常用治疗药物，对肠黏膜的炎症起着显著抑制作用。美沙拉嗪的应用虽有一定的治疗效果，但仍然难以在短时间内改善患者的各项症状，且患者治疗后有复发的可能[6-7]。随着研究的深入，通过对溃疡性结肠炎病因的分析，肠道菌群失调、免疫功能受损也参与诱导了该病的发生。因此，通过对患者肠道通透性的调节及平衡态的维持，可能发挥一定的治疗作用[8]。为此，本研究结合我院近期的临床实践经验，以双歧杆菌三联活菌胶囊联合美沙拉嗪治疗溃疡性结肠炎，现报道如下。

1 资料与方法

1.1 一般资料

收集2018年6月至2020年6月黑龙江省佳木斯市中心医院收治98例溃疡性结肠炎患者，分为观察组与对照组，每组各49例。……